Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma Urological oncology

Bishoy A. Gayed, Jessica Gillen, Alana Christie, Samuel Peña-Llopis, Xian-Jin Xie, Jingsheng Yan, Jose A. Karam, Ganesh Raj, Arthur I Sagalowsky, Yair Lotan, Vitaly Margulis, James B Brugarolas

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Abstract Background: To assess pathological correlations and temporal trends of Angiopoietin-2 (ANGPT2), vascular endothelial growth factor (VEGF) and M2 Pyruvate kinase (TuM2PK), markers of tumor vascular development and metabolism, in patients with renal cell carcinoma (RCC). Methods: We prospectively collected plasma samples from 89 patients who underwent surgical/ablative therapy for RCC and 38 patients with benign disease (nephrolithiasis, hematuria without apparent neoplastic origin, or renal cysts). In RCC patients, marker levels were compared between at least 1 preoperative and 1 postoperative time point generally 3 weeks after surgery. Marker temporal trends were assessed using the Wilcoxon sign-rank test. Plasma VEGF, ANGPT2, and TuM2PK levels were determined by ELISA and tested for association with pathological variables. Results: Median age was comparable between groups. 83/89 (93%) of the cohort underwent surgical extirpation. 82% of the tumors were organ confined (T ≤2, N0). Only ANGPT2 exhibited significantly elevated preoperative levels in patients with RCC compared to benign disease (p = 0.046). Elevated preoperative levels of ANGPT2 and TuM2PK significantly correlated with increased tumor size and advanced grade (p < 0.05). Chromophobe RCC exhibited higher levels of ANGPT2 compared to other histologies (p < 0.05). A decline in marker level after surgery was not observed, likely due to the timing of the analyses. Conclusion: Our results suggest that ANGPT2 is a marker of RCC. Additionally, ANGPT2 and TuM2PK significantly correlated with several adverse pathological features. Further studies are needed to determine clinical applicability.

Original languageEnglish (US)
Article number24
Pages (from-to)1-8
Number of pages8
JournalBMC Urology
Issue number1
StatePublished - Dec 1 2015


  • Angiogenesis
  • Biomarkers
  • Prospective
  • Renal cell carcinoma
  • Tumor metabolism

ASJC Scopus subject areas

  • Reproductive Medicine
  • Urology


Dive into the research topics of 'Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma Urological oncology'. Together they form a unique fingerprint.

Cite this